Quote | Aprea Therapeutics Inc. (NYSE:APRE)
Last: | $ |
---|---|
Change Percent: | -0.29% |
Open: | $34.88 |
Close: | $34.52 |
High: | $36.00 |
Low: | $34.11 |
Volume: | 25,629 |
Last Trade Date Time: | 02/12/2020 04:44:03 pm |
News | Aprea Therapeutics Inc. (NYSE:APRE)
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) pr...
2024-04-03 16:30:08 ET More on Aprea Therapeutics Aprea Therapeutics announces private placement financing of up to $34M Seeking Alpha’s Quant Rating on Aprea Therapeutics Historical earnings data for Aprea Therapeutics Financial information for Aprea ...
Message Board Posts | Aprea Therapeutics Inc. (NYSE:APRE)
Subject | By | Source | When |
---|---|---|---|
Dropping like a waterfall. | willlbone | investorshub | 11/11/2022 4:07:04 PM |
$APRE is climbing, it climbed today in spite | Nazirite | investorshub | 07/11/2022 8:22:41 PM |
Price target set for $3 buy and hold | Nazirite | investorshub | 07/11/2022 1:25:09 PM |
GM $APRE time to work | Nazirite | investorshub | 07/11/2022 12:51:35 PM |
High volume today 43x avg | Nazirite | investorshub | 07/08/2022 3:52:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatmen...
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) pr...
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase ...